Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-650,719 is a **carbonic anhydrase inhibitor** of the sulfonamide class, chemically named 6-hydroxybenzo[b]thiophene-2-sulfonamide. It was investigated as a topical agent to lower intraocular pressure for glaucoma therapy. L-650,719 is structurally characterized by a benzo-thiophene core with a sulfonamide group and hydroxyl substitution, conferring improved water solubility over earlier analogs. Topical administration in animal models lowered intraocular pressure, likely through carbonic anhydrase inhibition in ocular tissues. Its development was discontinued after clinical trials showed only modest efficacy in humans.[1][3][5][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on l-650,719.